Pair page
IGF-1 LR3 with MGF
Mechanism-tag overlap and published literature for IGF-1 LR3 and MGF, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
igf-1-receptor-agonistlong-r3-analogmodified-protein
igf-1-splice-variant-satellite-cell-activator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying IGF-1 LR3 and MGF have published these mechanism-level observations. Not a co-administration recommendation.
PEG-MGF combined with IGF-1 LR3 for comprehensive IGF-1 pathway coverage. PEG-MGF handles satellite cell recruitment; LR3 provides sustained systemic anabolic support. Aggressive stack with compounded risk profile — monitor glucose, IGF-1, blood pressure.
Quick facts
IGF-1 LR3
MGF
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2004 | IGF-1 LR3 | Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. (Epidemiologic IGF-1/cancer association.) | systematic review |
| 1999 | IGF-1 LR3 | Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. Horm Res. 1999;51(3):128-134. (Mecasermin European data.) | human study |
| 1993 | IGF-1 LR3 | Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-II. Biochem J. 1993;… | mechanism / discovery |
| 1992 | IGF-1 LR3 | Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological poten… | mechanism / discovery |
| 1992 | IGF-1 LR3 | King R, Wells JR, Krieg P, Snoswell M, Brazier J, Bagley CJ, Wallace JC, Ballard FJ, Ross M, Francis GL. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expre… | mechanism / discovery |
| 2026 | IGF-1 LR3 | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (All IGF-1 forms banned under S2.) | regulatory / registry |
| 2026 | IGF-1 LR3 | HHS Secretary Robert F. Kennedy Jr. Public Statement on Peptide Reclassification, February 27, 2026. (Reference for ongoing Category 2 → Category 1 review affecting IGF-1 family.) | regulatory / registry |
| 2025 | IGF-1 LR3 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (IGF-1 LR3 Category 2 designation.) | regulatory / registry |
| 2005 | IGF-1 LR3 | Increlex (mecasermin) FDA Approval Documentation. FDA Approval Date: August 31, 2005. Sponsor: Tercica (now Ipsen). Indication: severe primary IGF-1 deficiency in children. (Native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Thomas A, Solymos E, Schänzer W, Thevis M. Determination of insulin-like growth factor-I and IGF analogues in human serum by liquid chromatography-tandem mass spectrometry. (WADA detection methods for IGF-1 forms including LR3.) | regulatory / registry |
| — | IGF-1 LR3 | Ipsen Pharmaceuticals. Increlex (mecasermin) Prescribing Information. (FDA-approved native rhIGF-1; not IGF-1 LR3.) | regulatory / registry |
| 2009 | MGF | Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, Koutsilieris M. IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med. 2009;15(5-6):127-135. PMID: 19242589. PMID 19242589 | preclinical, in vivo |
| 2007 | MGF | Philippou A, Maridaki M, Halapas A, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo. 2007;21(1):45-54. PMID: 17354613. PMID 17354613 | preclinical, in vivo |
| 2003 | MGF | Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol. 2003;549(Pt 2):409-418. PMID: 12692182. DOI: 10.1113/jphysiol.2002.035832. PMID 12692182 | preclinical, in vivo |
| 2002 | MGF | Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-160. PMID: 12095642. DOI: 10.1016/s0014-5793(02)02918-6. PMID 12095642 | preclinical, in vitro |
| 2010 | MGF | Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865-875. PMID: 20130113. PMID 20130113 | mechanism / discovery |
| 2025 | MGF | WADA. World Anti-Doping Code: The 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2013 | MGF | Brisson BK, Barton ER. New modulators for IGF-I activity within IGF-I processing products. Front Endocrinol (Lausanne). 2013;4:42. PMID: 23626586. PMID 23626586 | research article |
| 2009 | MGF | Pfeffer LA, Brisson BK, Lei H, Barton ER. The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell. 2009;20(17):3810-3817. PMID: 19605555. PMID 19605555 | research article |
| 2008 | MGF | Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-39. PMID: 17881288. DOI: 10… PMID 17881288 | research article |
| 2007 | MGF | Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007;7(10):2247-2259. PMID: 17711551. PMID 17711551 | research article |
| 2007 | MGF | Philippou A, Halapas A, Maridaki M, Koutsilieris M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact. 2007;7(3):208-218. PMID: 17906394. PMID 17906394 | research article |
| 2005 | MGF | Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20:232-238. PMID: 16024512. DOI: 10.1152/physiol.00004.2005. PMID 16024512 | research article |
Related pair pages
More research context
Frequently asked
Have IGF-1 LR3 and MGF been studied together?
Researchers have published mechanistic-level co-administration discussion of IGF-1 LR3 and MGF. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do IGF-1 LR3 and MGF share?
IGF-1 LR3 and MGF do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of IGF-1 LR3 and MGF?
IGF-1 LR3: Research only (Category 2 bulk). MGF: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on IGF-1 LR3 and MGF?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the IGF-1 LR3 profile and the MGF profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026